

References

Chapter 19

Key references/suggested reading are marked with an asterisk.*

- 1 Babar ZU, Francis S. Identifying priority medicines policy issues for New Zealand: a general inductive study. *British Medical Journal Open*. 2014;**4**(5):e004415.
- 2 Drews J. Drug discovery: a historical perspective. *Science*. 2000;**287**(5460):1960–4.
- 3 Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. *Health Policy*. 2014;**116**(2–3):137–46.
- 4 Godman B, Campbell S, Suh HS, Finlayson A, Bennie M, Gustafsson L. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. *Journal of Health Technology Assessment*. 2013;**1**:27–42.
- 5 Organisation for Economic Co-operation and Development. Health at a Glance 2011. OECD Indicators. Pharmaceutical expenditure. Available from: <http://www.oecd.org/els/health-systems/49105858.pdf> (18 November 2015).
- 6 Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet*. 2009;**373**(9659):240–9.
- 7 Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European health care systems. *European Journal of Clinical Pharmacology*. 2008;**64**(12):1137–8.
- 8 Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: Findings from across Europe and their implications. *BMC Medicine*. 2014;**12**(1):98.
- 9 Godman B, Malmstrom RE, Diogene E, Jayathissa S, McTaggart S, Cars T, et al. Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. *Frontiers in Pharmacology*. 2014;**5**:109.
- 10 Lubloy A. Factors affecting the uptake of new medicines: a systematic literature review. *BMC Health Services Research*. 2014;**14**:469.
- 11 Kaplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority Medicines for Europe and the World 2013 Update. Available from: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1 (last accessed 18 November 2015).
- 12 Malmstrom RE, Godman BB, Diogene E, Baumgartel C, Bennie M, Bishop I, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. *Frontiers in Pharmacology*. 2013;**4**:39.
- 13 Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. *EuroHealth*. 2011;**17**:1–4.
- 14 Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? *Expert Review of Clinical Pharmacology*. 2015;**8**(1):77–94.
- 15 Campbell SM, Godman B, Diogene E, Furst J, Gustafsson LL, MacBride-Stewart S, et al. Quality indicators as a tool in improving the introduction of new medicines. *Basic & Clinical Pharmacology & Toxicology*. 2015;**116**(2):146–57.
- 16 Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrado S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in Pharmacology*. 2014;**5**:106.
- 17 Seiter A. A Practical Approach to Pharmaceutical Policy. Washington, DC, World Bank, 2010. Available from:

- <https://openknowledge.worldbank.org/bitstream/handle/10986/2468/552030PUB0Phar10Box349442B01PUBLIC1.pdf?sequence=4> (last accessed 18 November 2015). *Good overview of pharmaceutical policies across countries, including practical approaches.
- 18 Traulsen JM, Almarsdottir AB. The argument for pharmaceutical policy. *Pharmacy World & Science*. 2005;**27**(1):7–12. *Gives good background to pharmaceutical policies.
 - 19 Almarsdottir AB, Traulsen JM. Rational use of medicines – an important issue in pharmaceutical policy. *Pharmacy World & Science*. 2005;**27**(2):76–80. *Gives good background to pharmaceutical policies.
 - 20 Wagner AK, Graves AJ, Reiss SK, Lecates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. *Health Policy*. 2011;**100**(2–3):151–8.
 - 21 Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. *Journal of Global Health*. 2013;**3**(1):010303.
 - 22 Li X, Zhang W. The impacts of health insurance on health care utilization among the older people in China. *Social Science & Medicine*. 2013;**85**:59–65.
 - 23 Van Minh H, Kim Phuong NT, Saksena P, James CD, Xu K. Financial burden of household out-of pocket health expenditure in Viet Nam: findings from the National Living Standard Survey 2002–2010. *Social Science & Medicine*. 2013;**96**:258–63.
 - 24 European Federation of Pharmaceutical Industries and Associations. Health & Growth: Working Together for a Healthy Europe. A Vision Towards a Life Sciences Strategy for Europe. Brussels, European Federation of Pharmaceutical Industries and Associations, 2014. Available from: http://www.efpia.eu/uploads/documents/EFPIA-health&growth_MANIFESTO_V11_pbp.pdf (last accessed 18 November 2015).
 - 25 EvaluatePharma. Surveying Tomorrow's BioPharma Landscape. The NASDAQ Biotech Index Up Close. Available from: http://info.evaluatepharma.com/rs/evaluatepharmald/images/EvaluatePharma_NBI_Up_Close_2012.pdf (last accessed 18 November 2015).
 - 26 Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. *Generics and Biosimilars Initiative Journal*. 2014;**3**(1):34–5.
 - 27 Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. *Generics and Biosimilars Initiative Journal*. 2012;**1**(2):93–100.
 - 28 Ministry of Health Malaysia. Malaysian National Medicines Policy (DUNAS). Available from: <http://www.pharmacy.gov.my/v2/en/documents/malaysian-national-medicines-policy-dunas.html> (last accessed 18 November 2015).
 - 29 Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2009;**9**(1):65–83.
 - 30 Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. *Health Policy*. 2010;**94**(3):221–9.
 - 31 Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J, et al. The 'wise list' – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. *Basic & Clinical Pharmacology & Toxicology*. 2011;**108**(4):224–33.
 - 32 Almarsdottir AB, Traulsen JM. Cost-containment as part of pharmaceutical policy. *Pharmacy World & Science*. 2005;**27**(3):144–8. *Gives good background to pharmaceutical policies.
 - 33 Vogler S, Zimmermann N. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. *Generics and Biosimilars Initiative Journal*. 2013;**2**(2):65–75.
 - 34 Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. *Southern Medicine Review*. 2011;**4**(2):69–79.
 - 35 Rietveld AH, Haaijer-Ruskamp F. Policy options for cost containment of pharmaceuticals. In: Dukes MNG, Haaijer-Ruskamp FM, de Joncheere CP, Rietveld AH, eds. *Drugs and Money: Prices, Affordability and Cost Containment*. Amsterdam, IOS Press, 2003: 29–54. *Gives a good overview of policy options.
 - 36 Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Available from: <http://core.ac.uk/download/>

- pdf/16379320.pdf (last accessed 18 November 2015). *Good overview of managed entry strategies across Europe – their strengths as well as concerns.
- 37 Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Services Research*. 2010;**10**:153.
 - 38 Paris V, Belloni A. Value in Pharmaceutical Pricing. OECD Health Working Papers, No. 63. Washington, DC, OECD Publishing, 2013. Available from: <http://dx.doi.org/10.1787/5k43jc9v6knx-en> (last accessed 18 November 2015). *Provides a good overview of how countries assess pricing and reimbursement for new medicines, including issues of comparators and methods for economic evaluation.
 - 39 Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. *PLoS Medicine*. 2009;**6**(6):e1000084.
 - 40 Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T. Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. *BMJ Quality & Safety*. 2013;**22**(1):53–64.
 - 41 Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013;**13**(4):469–82.
 - 42 Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2011;**11**(3):343–9.
 - 43 Abuelkhair M, Abdu S, Godman B, Fahmy S, Malmstrom RE, Gustafsson LL. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2012;**12**(1):115–24.
 - 44 Sandheimer C, Karlberg I. Ten years experience with models for financing of outpatient prescriptions. *Health Policy and Technology*. 2013;**2**:188–95.
 - 45 Morgan SG, Thomson PA, Daw JR, Friesen MK. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. *Health Policy*. 2013;**112**(3):248–54.
 - 46 Morgan SG, Friesen MK, Thomson PA, Daw JR. Use of product listing agreements by Canadian provincial drug benefit plans. *Healthcare Policy*. 2013;**8**(4):45–55.
 - 47 Horn H, Nink K, McGauran N, Wieseler B. Early benefit assessment of new drugs in Germany – results from 2011 to 2012. *Health Policy*. 2014;**116**(2–3):147–53.
 - 48 Gerber A, Stock S, Dintios CM. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? *Pharmacoeconomics*. 2011;**29**(7):549–53.
 - 49 Godman B, Bucsecs A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2008;**8**(4):357–71.
 - 50 Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. *Applied Health Economics and Health Policy*. 2013;**11**(1):79–82.
 - 51 Ford JA, Waugh N, Sharma P, Sculpher M, Walker A. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. *British Medical Journal Open*. 2012;**2**(1):e000671.
 - 52 Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. *Journal of the American Medical Association*. 2009;**302**(13):1437–43.
 - 53 Yim EY, Lim SH, Oh MJ, Park HK, Gong JR, Park SE, et al. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea. *Value in Health*. 2012;**15**(1 Suppl.):S104–10.
 - 54 Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. *Applied Health Economics and Health Policy*. 2009;**7**(3):137–47.
 - 55 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance

- prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2010;**10**(6):707–22.
- 56 Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2011;**11**(4):469–79.
- 57 Moon JC, Godman B, Petzold M, Alvarez-Madrazo S, Bennett K, Bishop I, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. *Frontiers in Pharmacology*. 2014;**5**:219.
- 58 Sketris I, Ingram E, Lummis H. Optimal prescribing and medication use in Canada – challenges and opportunities. Available from: http://healthcouncil-canada.ca/tree/2.37.1-Appendices_OptimizingPrescribingBehaviours.pdf (last accessed 18 November 2015).
- 59 Tordrup D, Angelis A, Kanavos P. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey. *Applied Health Economics and Health Policy*. 2013;**11**(6):639–52.
- 60 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in Pharmacology*. 2010;**1**:141.
- 61 Cacace M, Ettelt S, Mays N, Nolte E. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. *Health Policy*. 2013;**112**(1–2):156–62. *Provides good advice for undertaking CNC studies.
- 62 Wettermark B. The intriguing future of pharmacoepidemiology. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):43–51. *Gives examples of potential drug utilization studies that can be undertaken given certain datasources.
- 63 Almarsdottir AB, Traulsen JM. Studying and evaluating pharmaceutical policy – becoming a part of the policy and consultative process. *Pharmacy World & Science*. 2006;**28**(1):6–12. *Gives good background to pharmaceutical policies.
- 64 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *Journal of Clinical Pharmacy and Therapeutics*. 2002;**27**(4):299–309. *Good background methodology chapter.
- 65 Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. *British Medical Journal*. 1998;**317**(7156):465–8.
- 66 Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. *Family Practice*. 2000;**17**(Suppl. 1):S11–16.
- 67 Australian Government Department of Health and Ageing. National Medicines Policy 2000. Available from: [http://www.health.gov.au/internet/main/publishing.nsf/Content/B2FFBF72029EEAC8CA257BF0001BAF3F/\\$File/NMP2000.pdf](http://www.health.gov.au/internet/main/publishing.nsf/Content/B2FFBF72029EEAC8CA257BF0001BAF3F/$File/NMP2000.pdf) (last accessed 18 November 2015).
- 68 Australian Government Department of Health and Ageing. The National Strategy for Quality Use of Medicines – Executive Summary. Available from: [http://www.health.gov.au/internet/main/publishing.nsf/Content/46121C0B732612B9CA257BF0001CFED0/\\$File/execumbro.pdf](http://www.health.gov.au/internet/main/publishing.nsf/Content/46121C0B732612B9CA257BF0001CFED0/$File/execumbro.pdf) (last accessed 18 November 2015).
- 69 NPS MedicineWise. About Us. Available from: <http://www.nps.org.au/about-us> (last accessed 18 November 2015).
- 70 Weekes LM, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. *British Journal of Clinical Pharmacology*. 1996;**42**(5):551–7.
- 71 Tan EL, Day RO, Brien JA. Prioritising drug and therapeutics committee (DTC) decisions: a national survey. *Pharmacy World & Science*. 2007;**29**(2):90–6.
- 72 Stafinski T, Menon D, McCabe C, Philippon DJ. To fund or not to fund: development of a decision-making framework for the coverage of new health technologies. *Pharmacoeconomics*. 2011;**29**(9):771–80.
- 73 Morgan SG, Thomson PA, Daw JR, Friesen MK. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces. *BMC Health Services Research*. 2013;**13**:34.
- 74 Khan S, Moore JE, Gomes T, Camacho X, Tran J, McAuley G, et al. The Ontario Drug Policy Research Network: bridging the gap between Research and Drug Policy. *Health Policy*. 2014;**117**(3):392–8.

- 75 Kim Y, Yang B. Relationship between catastrophic health expenditures and household incomes and expenditure patterns in South Korea. *Health Policy*. 2011;**100**(2–3):239–46.
- 76 Kwon H-Y, Yang B, Godman B. Key components of increased drug expenditure in South Korea; implications for the future. *Value in Health Regional Issues*. 2015;**6**:14–21
- 77 Gauld R. Ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary. *Pharmacoeconomics*. 2014;**32**(10):937–42.
- 78 Babar ZUD, Vitry A. Differences in Australian and New Zealand medicines funding policies. *Australian Prescriber*. 2014;**37**:150–1.
- 79 Metcalfe S, Grocott R, Rasiah D. Comment on 'Ahead of Its Time? Reflecting on New Zealand's Pharmac Following its 20th Anniversary': clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise). *Pharmacoeconomics*. 2014;**32**(10):1031–3.
- 80 Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. *New Zealand Medical Journal*. 2011;**124**(1346):12–28.
- 81 Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):73–8.
- 82 Wettermark B, Godman B, Eriksson C, van Ganse E, Garattini S, Joppi R, et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme [Introduction of new medicines into European healthcare systems]. *GGW*. 2010;**10**(3):24–34.
- 83 Godman B, Burkhardt T, Bucsecs A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2009;**9**:475–84.
- 84 Mao W, Tang S, Chen W. Does perverse economic incentive lead to the irrational uses of medicines? *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013;**13**(6):693–6.
- 85 Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. *BMC Health Services Research*. 2013;**13**(1):390.
- 86 Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. *Health Policy*. 2014;**116**(2–3):214–23.
- 87 Fürst J, Čiznab M, Mrak J, Kos D, Campbell S, Coenen S, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade; findings and implications. *Expert Review of Anti-Infective Therapy*. 2015;**13**(2):279–89.
- 88 Reynolds L, McKee M. Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system. *International Journal of Health Planning and Management*. 2011;**26**(4):449–70.
- 89 Kiviniemi V, Peura P, Helin-Salmivaara A, Martikainen JE, Hartikainen J, Huupponen R, et al. Suboptimal use of statins at treatment initiation. *European Journal of Clinical Pharmacology*. 2011;**67**(9):971–3.
- 90 Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. *Archives of Internal Medicine*. 2006;**166**(3):332–7.
- 91 Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. *Pharmacoeconomics and Drug Safety*. 2005;**14**(5):341–8.